The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.03.004
- Author:
Yan-Na WANG
1
;
Tong WEI
1
;
Ya-Ming XI
2
,
3
;
Ming-Yue YANG
1
;
Lu NIU
1
;
Xiao-Ling WANG
1
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, Lanzhou University First Hospital
3. Lanzhou 730000, Gansu Province, China,E-mail：xiyaming02@163.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Body Mass Index;
Cytarabine/therapeutic use*;
Female;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(3):677-684
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analysis the relationship between different BMI (body mass index) and the clinical characteristics, laboratory examination indexes of newly diagnosed adult patients with acute myeloid leukemia (AML), so as to investigate the effects of BMI to the efficacy of first induction chemotherapy.
METHODS:The clinical data of 145 newly diagnosed adult AML patients treated in the First Hospital of Lanzhou University from August 2015 to August 2019 were retrospective analyzed. According to the guidelines for prevention and control of overweight and obesity in Chinese adults, the BMI (kg/m
RESULTS:Among the 145 newly diagnosed adult AML patients, there were 71 males and 74 females. The median age was 50 years old(range 18 to 82 years old). There were 21 patients in underweight group (14.5%), 79 patients in normal weight group (54.5%), and 45 patients in overweight and obese group (31.0%). The patients with higher BMI level showed the older in age（P=0.018）. There were significant differences in sex between the patients in each group(P=0.035). In overweight and obese patients, the number of male was significantly higher than female. There were no statistical differences in AML classification, comorbidities(Diabetes, hypertension, coronary heart disease), hospital days, whether secondary AML and FLT3 gene mutation among the patients in different BMI groups. There were significant differences in TG of the patients in the different groups, the overweight and obese patients were higher (P=0.007). There were no significant differences in WBC and Hb counts, ALB, TC, HDL, LDL, or LDH between the patients in each BMI group at newly diagnosed. The complete remission rate of the patients in the low body mass group or overweight and obese group were lower than that in the normal body weight group (P=0.035). The rate of documented infection during the first induction chemotherapy were significantly higher for the patients in low body mass group than those in normal weight group or overweight and obese group (P=0.038). There was no statistical difference in chemotherapy regimens, the number of chemotherapy until CR, febrile neutropenia, bleeding, and the time of neutropenia, liver and kidney toxicity among each BMI group. Multivariate analysis showed that overweight and obese (P=0.012) , FLT3 mutation (P=0.015) were the risk factors affecting the CR rate of the patients. And the patients with secondary AML, high-risk type, and newly diagnosed WBC ≥50×10
CONCLUSION:In newly diagnosed adult patients with AML, low body mass, overweight and obesity, and FLT3 mutations were the factors reducing the early efficacy of AML patients. There were more adverse reactions induced by chemotherapy in the low body mass group. Therefore, inappropriate BMI level can be a risk factor for assessing the prognosis of adults with newly diagnosed AML.
